← Back to all signals
RESEARCH PAPER ANALYSIS

Integrating 3D bioprinting and neural stem cell therapy for central nervous system repair: implications for regenerative neurosurgery.

This review argues that combining 3D bioprinted scaffolds with neural stem cell therapy can address key barriers to CNS regeneration by detailing bioink/scaffold design, biophysical and biochemical cues, and summarizing 53 preclinical and 18 early clinical studies across spinal cord injury, stroke,…

PMID41982329
JournalFrontiers in bioengineering and biotechnology
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This review argues that combining 3D bioprinted scaffolds with neural stem cell therapy can address key barriers to CNS regeneration by detailing bioink/scaffold design, biophysical and biochemical cues, and summarizing 53 preclinical and 18 early clinical studies across spinal cord injury, stroke,…

WHY IT MATTERS

Research significance

By synthesizing scaffold engineering, vascularization, immune compatibility, and GMP manufacturing challenges, the paper highlights practical strategies that could improve stem-cell survival, integration, and translational readiness for Parkinson’s cell-replacement and disease-modeling applications.

ABSTRACT

Source abstract

The limited regenerative capacity of the central nervous system (CNS)poses a major challenge in neurosurgical interventions for spinal cord injuries, neurodegenerative diseases,and traumatic brain injuries. Traditional approaches offer structural stabilization but rarely achieve true neural tissue regeneration. Recent advances in regenerative medicine have spotlighted two promising strategies: 3D bioprinting and neural stem cell (NSC) therapy.3D bioprinting enables the fabrication of anatomically precise, biocompatible scaffolds that mimic native neural architecture, offering structural and biochemical support for tissue repair. Concurrently, NSCs capable of differentiating into neurons, astrocytes, and oligodendrocytes promote neurogenesis, synaptic integration,and immune modulation, making them attractive candidates for functional recovery. Despite extensive preclinical success, clinical translation of neural stem cell therapy remains inconsistent due to poor cell survival, uncontrolled differentiation, limited graft integration, and hostile post-injury microenvironments. This review critically examines why these limitations persist and argues that 3D bioprinting is not merely complementary, but essential for overcoming fundamental barriers to effective CNS regeneration. This review critically examines the convergence of 3D bioprinting and NSC therapy in neurosurgical applications. It discusses the design of bioinks, scaffold fabrication techniques,and the role of conductive and ECM-derived materials in supporting NSC viability and differentiation. The manuscript also explores preclinical and early-phase clinical trials (2015-2025), highlighting the therapeutic potential of NSC-loaded bioprinted constructs in spinal cord injury, Parkinson's disease,and stroke. Further, we analyze the biophysical and biochemical cues within scaffolds that shape NSC fate and describe how 3D bioprinted models are being used for disease modeling and drug screening. This review synthesizes findings from 53 preclinical and 18 clinical studies published between 2015 and 2025, providing a first-of-its-kind analysis that integrates bioink engineering principles with NSC-specific regenerative cues in neurosurgical applications. Our findings highlight that scaffold vascularization, immune compatibility,and GMP-standardized manufacturing remain the most pressing translational challenges,yet convergence of these technologies has the potential to redefine functional CNS repair. Despite promising outcomes, clinical translation faces challenges including cell survival, vascular integration, scaffold standardization,and regulatory compliance. Emerging technologies such as 4D bioprinting,CRISPR-engineered NSCs,and organoid-on-a-chip platforms are poised to overcome these barriers. By integrating structural bioengineering with cellular therapy, this interdisciplinary approach holds transformative potential for CNS repair. This review aims to provide a comprehensive overview of current advancements, translational bottlenecks,and future directions in regenerative neurosurgery using bioprinted NSC-based constructs.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic